Dongsung Pharmaceutical Co., Ltd.(KR:002210)
₩1,026.00+6.00 (+0.59%)
KR:002210
Dongsung Pharmaceutical Co., Ltd. financials statements
₩1,026.00
At close:+6.00 (+0.59%)
Want to see KR:002210 full AI Analyst Report?
Dongsung Pharmaceutical Co., Ltd. (002210) Ratios
Dongsung Pharmaceutical Co., Ltd. Ratios
KR:002210's free cash flow for Q2 2026 was ₩-20.04B. For the 2026 fiscal year, KR:002210's free cash flow was decreased by ₩-496.90M and operating cash flow was ₩-19.54B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.69 | 0.88 | 1.36 | 1.14 | 1.33 |
| Quick Ratio | 0.54 | 0.59 | 0.92 | 0.83 | 0.92 |
| Cash Ratio | 0.03 | 0.04 | 0.14 | 0.09 | 0.08 |
| Solvency Ratio | -0.16 | -0.06 | -0.00 | -0.00 | -0.04 |
| Operating Cash Flow Ratio | -0.10 | -0.13 | -0.10 | -0.08 | -0.07 |
| Short-Term Operating Cash Flow Coverage | -0.20 | -0.19 | -0.17 | -0.13 | -0.14 |
| Net Current Asset Value | ₩ -56.18B | ₩ -28.58B | ₩ -14.36B | ₩ -10.50B | ₩ -8.16B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.38 | 0.34 | 0.38 | 0.34 | 0.28 |
| Debt-to-Equity Ratio | 2.74 | 0.94 | 1.09 | 0.87 | 0.63 |
| Debt-to-Capital Ratio | 0.73 | 0.49 | 0.52 | 0.46 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.01 | 0.32 | 0.15 | 0.17 |
| Financial Leverage Ratio | 7.21 | 2.75 | 2.89 | 2.52 | 2.25 |
| Debt Service Coverage Ratio | -0.24 | -0.03 | 0.08 | 0.04 | -0.08 |
| Interest Coverage Ratio | -2.35 | -1.76 | 0.27 | -1.56 | -7.44 |
| Debt to Market Cap | 2.88 | 0.49 | 0.32 | 0.24 | 0.15 |
| Interest Debt Per Share | 3231.02 | 2441.69 | 1990.46 | 1666.84 | 1284.66 |
| Net Debt to EBITDA | -2.91 | -23.88 | 10.77 | 21.57 | -15.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.71% | 43.96% | 46.70% | 45.06% | 39.74% |
| EBIT Margin | -26.23% | -4.43% | 1.55% | -0.58% | -4.34% |
| EBITDA Margin | -23.78% | -2.32% | 3.86% | 1.64% | -2.05% |
| Operating Profit Margin | -26.23% | -7.45% | 0.67% | -2.19% | -6.28% |
| Pretax Profit Margin | -32.91% | -8.66% | -0.98% | -1.98% | -5.19% |
| Net Profit Margin | -29.53% | -8.20% | -2.34% | -2.27% | -5.11% |
| Continuous Operations Profit Margin | -29.53% | -8.20% | -2.34% | -2.27% | -5.11% |
| Net Income Per EBT | 89.71% | 94.74% | 239.51% | 114.65% | 98.48% |
| EBT Per EBIT | 125.46% | 116.12% | -145.18% | 90.64% | 82.64% |
| Return on Assets (ROA) | -15.28% | -4.77% | -1.80% | -1.97% | -4.12% |
| Return on Equity (ROE) | -110.12% | -13.14% | -5.21% | -4.96% | -9.29% |
| Return on Capital Employed (ROCE) | -59.02% | -8.81% | 0.85% | -3.40% | -7.91% |
| Return on Invested Capital (ROIC) | -19.94% | -4.94% | 0.63% | -2.28% | -6.02% |
| Return on Tangible Assets | -15.32% | -4.80% | -1.82% | -1.99% | -4.16% |
| Earnings Yield | -115.68% | -6.85% | -1.54% | -1.38% | -2.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.01 | 2.46 | 2.83 | 2.82 | 3.03 |
| Payables Turnover | 4.39 | 4.14 | 4.19 | 5.16 | 7.42 |
| Inventory Turnover | 2.61 | 2.18 | 2.42 | 3.43 | 3.28 |
| Fixed Asset Turnover | 1.21 | 1.20 | 2.07 | 2.12 | 2.26 |
| Asset Turnover | 0.52 | 0.58 | 0.77 | 0.87 | 0.81 |
| Working Capital Turnover Ratio | -3.51 | 24.95 | 7.78 | 9.71 | 4.68 |
| Cash Conversion Cycle | 147.63 | 227.83 | 192.42 | 164.96 | 182.80 |
| Days of Sales Outstanding | 90.94 | 148.51 | 128.92 | 129.38 | 120.66 |
| Days of Inventory Outstanding | 139.88 | 167.46 | 150.54 | 106.31 | 111.36 |
| Days of Payables Outstanding | 83.19 | 88.13 | 87.04 | 70.74 | 49.22 |
| Operating Cycle | 230.83 | 315.96 | 279.46 | 235.69 | 232.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -562.42 | -434.84 | -187.76 | -168.78 | -117.72 |
| Free Cash Flow Per Share | -619.10 | -542.71 | -228.15 | -196.73 | -217.13 |
| Dividend Paid and CapEx Coverage Ratio | -9.92 | -4.03 | -4.65 | -6.04 | -1.18 |
| Capital Expenditure Coverage Ratio | -9.92 | -4.03 | -4.65 | -6.04 | -1.18 |
| Operating Cash Flow Coverage Ratio | -0.20 | -0.19 | -0.10 | -0.10 | -0.09 |
| Operating Cash Flow to Sales Ratio | -0.15 | -0.11 | -0.05 | -0.04 | -0.03 |
| Free Cash Flow Yield | -63.63% | -11.72% | -3.87% | -2.94% | -2.59% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.86 | -14.58 | -65.05 | -72.64 | -45.42 |
| Price-to-Sales (P/S) Ratio | 0.26 | 1.20 | 1.52 | 1.65 | 2.32 |
| Price-to-Book (P/B) Ratio | 0.95 | 1.92 | 3.39 | 3.60 | 4.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.57 | -8.53 | -25.86 | -34.06 | -38.59 |
| Price-to-Operating Cash Flow Ratio | -1.73 | -10.65 | -31.42 | -39.70 | -71.19 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.06 | 39.21 | 1.45 | 0.66 |
| Enterprise Value Multiple | -3.98 | -75.52 | 50.20 | 122.50 | -128.32 |
| Enterprise Value | 82.52B | 154.82B | 171.75B | 187.07B | 222.04B |
| EV to EBITDA | -3.98 | -75.52 | 50.20 | 122.50 | -128.32 |
| EV to Sales | 0.95 | 1.75 | 1.94 | 2.00 | 2.63 |
| EV to Free Cash Flow | -5.83 | -12.48 | -32.92 | -41.34 | -43.75 |
| EV to Operating Cash Flow | -6.42 | -15.57 | -40.00 | -48.18 | -80.70 |
| Tangible Book Value Per Share | 1000.89 | 2383.96 | 1697.87 | 1823.76 | 1946.56 |
| Shareholders’ Equity Per Share | 1022.08 | 2413.11 | 1740.68 | 1860.97 | 1986.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.10 | 0.05 | -1.40 | -0.15 | 0.02 |
| Revenue Per Share | 3812.16 | 3868.11 | 3874.47 | 4057.08 | 3611.27 |
| Net Income Per Share | -1125.56 | -317.20 | -90.70 | -92.23 | -184.52 |
| Tax Burden | 0.90 | 0.95 | 2.40 | 1.15 | 0.98 |
| Interest Burden | 1.25 | 1.96 | -0.63 | 3.41 | 1.19 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 |
| SG&A to Revenue | 0.63 | 0.31 | 0.30 | 0.31 | 0.27 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.50 | 1.37 | 2.07 | 1.83 | 0.64 |
Currency in KRW

